Skip to main content
. 2019 Apr 6;15(12):2091–2106. doi: 10.1080/15548627.2019.1596493

Figure 8.

Figure 8.

Blockade of CD36 ameliorates elevated phagocytosis and increases CD4+ T-cell priming. (a) BMDCs from Atg5f/f or ITGAX/CD11c-atg5−/- mice were co-cultured with DiI-labeled apoptotic tumor cells in the presence of anti-mouse CD36 blocking antibody. Phagocytosis of dendritic cells was measured with flow cytometry. (b) Frequency of phagocytosis shown as bar graph (Student t-test, * P < 0.05). Data represent 3 independent experiments. (c) Atg5f/f or ITGAX/CD11c-atg5−/- splenic dendritic cells were co-cultured with apoptotic EG7 and OT-II CD4+ T cells with or without anti-mouse CD36 blocking antibody for 96 h. IFNG/IFN-γ production in the supernatant were measured with ELISA (Student t-test; **P < 0.01; ***P < 0.001; ****P < 0.0001). Data represents 2 independent experiments. (d) EG7 tumor-bearing Atg5f/f or ITGAX/CD11c-atg5−/- mice were injected intratumorally with anti-mouse CD36 blocking antibody at day 11, 13, and 15 after EG7 inoculation. Tumor size was monitored with a digital caliper (5 mice per group; two-way ANOVA; *P < 0.05; ***P < 0.001). Data are representative of 2 independent experiments.